GoodRx (NASDAQ:GDRX) Stock Price Down 8.4% After Analyst Downgrade

Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) were down 8.4% during mid-day trading on Monday after Citigroup lowered their price target on the stock from $7.00 to $6.25. Citigroup currently has a buy rating on the stock. GoodRx traded as low as $4.16 and last traded at $4.17. Approximately 959,968 shares were traded during trading, a decline of 25% from the average daily volume of 1,288,451 shares. The stock had previously closed at $4.55.

A number of other brokerages have also recently weighed in on GDRX. Mizuho began coverage on shares of GoodRx in a report on Wednesday, December 4th. They set a “neutral” rating and a $5.00 target price on the stock. Barclays dropped their price objective on shares of GoodRx from $10.00 to $6.00 and set an “overweight” rating on the stock in a research note on Monday, November 11th. Morgan Stanley decreased their target price on GoodRx from $7.00 to $6.00 and set an “equal weight” rating for the company in a research note on Tuesday, December 17th. Finally, KeyCorp dropped their price target on GoodRx from $7.00 to $6.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 8th. Five analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $8.38.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Fortem Financial Group LLC raised its stake in shares of GoodRx by 7.2% during the fourth quarter. Fortem Financial Group LLC now owns 119,179 shares of the company’s stock valued at $554,000 after purchasing an additional 7,996 shares in the last quarter. JPMorgan Chase & Co. raised its position in shares of GoodRx by 358.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 24,293 shares of the company’s stock worth $169,000 after buying an additional 18,997 shares in the last quarter. Franklin Resources Inc. acquired a new stake in shares of GoodRx in the 3rd quarter worth approximately $5,675,000. Sanctuary Advisors LLC bought a new position in shares of GoodRx in the third quarter valued at approximately $85,000. Finally, Barclays PLC boosted its holdings in shares of GoodRx by 1,316.1% in the third quarter. Barclays PLC now owns 140,113 shares of the company’s stock valued at $973,000 after acquiring an additional 130,219 shares in the last quarter. Institutional investors own 63.77% of the company’s stock.

GoodRx Stock Down 1.7 %

The firm has a market cap of $1.58 billion, a price-to-earnings ratio of -138.33, a price-to-earnings-growth ratio of 3.43 and a beta of 1.27. The company has a quick ratio of 5.48, a current ratio of 5.48 and a debt-to-equity ratio of 0.70. The stock’s 50 day moving average is $4.65 and its 200 day moving average is $6.50.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.